IDEAYA Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Ryuk Byun - Morgan Stanley - Analyst : <_ALACRA_META_ABSTRACT>So maybe just to get us kicked off here Yujiro, can you just start by taking us through IDEAYA's pipeline and your oncology platforms?

Question: Ryuk Byun - Morgan Stanley - Analyst : Great. Thank you. We'll get into each of your pipeline assets to double click on them. But as you think about IDEAYA and this rich pipeline that you've built and talk thinking about the platform, how would you characterize IDEAYA and what's a core part of your story?

Question: Ryuk Byun - Morgan Stanley - Analyst : Great. Thank you. Maybe let's dive into the lead program, which I think most people are very familiar with, with daro and metastatic uveal melanoma. Now you've previously presented really compelling data on daro and crizo combination trial. And now you're preparing for the registrational trial and HLA negative subtype specifically. Now, can you walk us through the strategy on focusing on HLA negative patients and any conversations you might have had with the regulatory agencies?

Question: Ryuk Byun - Morgan Stanley - Analyst : Now is there -- that's great that you're focusing on HLA negative, which obviously is a larger opportunity. Is there a possibility that you will enroll additional HLA positive patients for expansion cohorts in this trial? And as you think about that market, obviously contracts there, how do you think about your place in the market?

Question: Ryuk Byun - Morgan Stanley - Analyst : Got it. Thank you, and also congratulations on getting your neoadjuvant Phase 2 trial up and running, how do you plan to leverage the neoadjuvant endpoints, such as reduction of radiation and eye preservation to further demonstrate clinical efficacy? And what are some of the key updates that we could potentially anticipate?

Question: Ryuk Byun - Morgan Stanley - Analyst : Got it. Thank you. And in terms of the registrational trials, you haven't really provided detailed guidance in terms of how the street or investors are thinking about the timeline, do you think there's a consensus on approximate timeline to approval? And as you think about that, what's your view on anticipated pace of enrollment for the registrational trial relative to your recent Phase 2 experience?

Question: Ryuk Byun - Morgan Stanley - Analyst : Got it. So even with site activation outside of the Europe that you will see updates from that. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 11, 2023 / 2:40PM, IDYA.OQ - IDEAYA Biosciences Inc at Morgan Stanley Global Healthcare Conference

Question: Ryuk Byun - Morgan Stanley - Analyst : Yeah, got it. Thank you. Before we switch gears to kind of what might be the -- getting interest from investors on 397, can you just talk a little bit about the activity that you've seen in daro relative to your competitors?

Question: Ryuk Byun - Morgan Stanley - Analyst : Right. And I think there's been just very clear, resounding excitement from investors around PRMT5 pathway, especially in reaction to what folks saw recently from Amgen, Mirati. Now, can you just walk us through the importance of this pathway from your perspective and the potential market opportunity?

Question: Ryuk Byun - Morgan Stanley - Analyst : Got it. And to keep things a little bit interesting, what's your perspective on some of the data that we've seen recently from some of your competitors.

Question: Ryuk Byun - Morgan Stanley - Analyst : And how do you think about the opportunity here for you? And obviously, there are like Tango is also in this space, but how do you think about the opportunity here for you in IDEAYA and also maybe around your partnership with Amgen going forward?

Question: Ryuk Byun - Morgan Stanley - Analyst : Yeah. It really makes a lot of sense from the complementary nature of MAT2A and PRMT5, but now, how do you think about the potential monotherapy opportunity?

Question: Ryuk Byun - Morgan Stanley - Analyst : Got it. Thank you. Now maybe you can tell us a little bit more around 161 and the PARG opportunity, including today's update.

Question: Ryuk Byun - Morgan Stanley - Analyst : Got it. And obviously, dose optimization efforts are ongoing, what are some of the clinical updates that we could potentially expect from that 161 program?

Question: Ryuk Byun - Morgan Stanley - Analyst : Got it. Now are you -- given kind of lot of good progress that you've made in identifying rational combination approaches, have you thought about a potential combination approaches that may be sensible for PARG?

Question: Ryuk Byun - Morgan Stanley - Analyst : Got it. Thank you. Then it's -- you have a new update almost every month or every other month, so hard to cover. Now, also congratulations on the Pol Theta IND clearance, do you have any color on potential endpoints that will demonstrate signs of efficacy? And also, as you think about the different indications, are there any specific tumors that you plan on targeting?

Question: Ryuk Byun - Morgan Stanley - Analyst : Got it. Now, maybe Paul, could you maybe talk -- obviously, good to have all these updates coming out, you know, in kind of like a bullet, every couple of months, but as you think about that capital intensity and maybe also talk a little bit about the business model in terms of how -- you have so many programs to prosecute and push through the clinic, how are you thinking about the capital strategy for IDEAYA?

Question: Ryuk Byun - Morgan Stanley - Analyst : Yeah.

Question: Ryuk Byun - Morgan Stanley - Analyst : Yeah, great. Thank you. In terms of some of the key milestones, I think we've talked about most of those earlier, but maybe just to summarize, what are some of the key updates that investors should pay attention to from your perspective in the next 6 to 12 months? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 11, 2023 / 2:40PM, IDYA.OQ - IDEAYA Biosciences Inc at Morgan Stanley Global Healthcare Conference

Question: Ryuk Byun - Morgan Stanley - Analyst : Got it. Great. I think we have about a minute left. Can you talk about your vision for the company? I think you've been able to succeed in proving out the synthetic lethal narrative where others have struggled. But now I think what you're turning into is really a broad oncology precision platform with some of your own, not only chemistry work, but also there's a machine learning component as well, you know, fast forward, like what's your ambition and vision for IDEAYA?

Question: Ryuk Byun - Morgan Stanley - Analyst : Got it. And yes, I think we're about time, but thank you again for making time to come, truck your way to New York for the conference. Your assets, each asset I think, are really strong and solid enough to creating a company. So you effectively have a private company and a platform behind it. Good luck with your meetings today, and we'll stay in touch. Thank you.